Organon pursues new solutions in high-need areas of women’s health with investment in Claria Medical

Agreement will support development of investigational medical device for minimally invasive hysterectomy

Organon on Thursday announced it has invested in Claria Medical Inc., a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy.

The agreement also grants Organon the option to acquire Claria Medical.

Under the terms of the agreement, Organon will pay $8 million upfront and have the option to acquire Claria Medical for predefined terms. The $8 million upfront payment will be classified as an in-process research & development expense in 2023.

“Hysterectomy is one of the most commonly performed surgeries for women, which is why it is critical to invest in new technology with the goal of providing safer, simpler and faster procedures,” Kevin Ali, Organon’s CEO, stated. “Collaborations such as our agreement with Claria Medical are integral to our business development approach. We search across the entire horizon for potential solutions — be they medicines, devices or other technologies —  that can improve the health of women. This agreement builds on our experience in devices and aligns with our focus on advancing urgently needed innovations.”

Claria’s initial investigational device, the Claria System, uses an intelligent uterine containment and extraction system that aims to improve the hysterectomy procedure for both patients and physicians.

Alexey Salamini, Claria Medical’s CEO, commented: “Our team is excited to enter this strategic agreement with Organon, who brings extensive knowledge in women’s health. Organon’s investment reinforces the potential of our technology to help improve outcomes for women. We look forward to continuing our clinical program for the Claria System and obtaining clearance from the U.S. Food and Drug Administration.”